Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 18.72M | 31.25M | 29.75M | 6.76M | 6.48M |
Gross Profit | 3.46M | 13.17M | 17.79M | 2.05M | 1.35M |
EBITDA | -51.72M | -117.56M | -84.36M | -65.06M | -48.20M |
Net Income | -132.06M | -88.48M | -88.66M | -114.28M | -51.15M |
Balance Sheet | |||||
Total Assets | 220.33M | 197.41M | 254.60M | 251.21M | 70.78M |
Cash, Cash Equivalents and Short-Term Investments | 113.59M | 119.11M | 229.81M | 225.66M | 54.13M |
Total Debt | 0.00 | 426.00K | 684.00K | 693.00K | 11.26M |
Total Liabilities | 64.77M | 40.23M | 56.98M | 53.87M | 33.13M |
Stockholders Equity | 155.55M | 157.18M | 197.62M | 197.34M | 37.65M |
Cash Flow | |||||
Free Cash Flow | -20.20M | -79.63M | -68.17M | -52.44M | -39.09M |
Operating Cash Flow | -20.07M | -78.33M | -67.57M | -52.13M | -38.63M |
Investing Cash Flow | -69.77M | 46.22M | 12.63M | -167.63M | 6.39M |
Financing Cash Flow | 74.54M | 26.71M | 72.87M | 225.05M | 18.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | ¥354.29B | 10.98 | -2.99% | 2.48% | 11.72% | -10.32% | |
61 Neutral | $161.55M | ― | -87.94% | ― | 3.89% | 7.92% | |
58 Neutral | $298.83M | ― | -152.14% | ― | 22.16% | -37.60% | |
55 Neutral | $122.11M | ― | -1552.23% | ― | 25.46% | 21.83% | |
52 Neutral | $118.29M | ― | -41.36% | ― | -44.17% | 12.77% | |
47 Neutral | $73.86M | ― | -47.95% | ― | -13.09% | -15.29% | |
46 Neutral | $181.91M | ― | -91.03% | ― | -40.09% | -18.67% |
Aclaris Therapeutics has updated its corporate overview presentation, highlighting the progress and potential of its drug candidates, including ATI-045, ATI-052, and ATI-2138. The company is well-positioned financially, with a strong cash runway expected to support operations into 2028, and is leveraging its expertise in small and large molecule discovery to advance its pipeline. This update suggests a solid trajectory for Aclaris in its market, potentially enhancing its position in the biotechnology industry and providing significant opportunities for stakeholders.